Aging, Dementia & Memory Management Guide

1. Brain Aging Dementia & management • Dean Sherzai MD, MAS, PhD(c) Director of Loma Linda Memory and Aging Center Director of Loma Linda University Neurology Research Program

2. Normal Aging

3. CENTENARIANS 1900 – RARE 1982 – 32,000 1998 – 61,000 2050 – 600,000

4. SUPER-CENTENARIANS

5. Active Aging Artists: Picasso > 90 T. Vecellio (Titian) > 90 Michelangelo sculpted at 89 Composers: Verdi wrote Falstaff at 84 Scientists: Galileo > 70 Linus Pauling > 80 Performers: Martha Graham danced till 75 choreographed @ 95 Artur Rubinstein last recital at 93 Writers: too numerous to mention ...

6. Definitions • Normal Brain Aging • Mild Cognitive Impairment • Dementia

7. Aging, memory and intellect Don’t change Decrease • Speed of memory retrieval • Speed of processing • Multi-tasking ability • Memory-formation efficiency Verbal IQ Vocabulary Store of information Comprehension

8. Common Cognitive Complaints in Normal Adults SituationPercentage of elderly Names 83 % Where I put things 60 % Knowing I have told someone 49 % something Forgetting a task after starting 41 % Losing the thread of conversation 40 % From: Boller et al, Arch Neurol 1991

9. Brain Changes With Aging • Brain weight: • Decreases by about 0.5% per year after age 30 • Neuron loss: • Region-specific • 10-25% loss in cerebellum, cortex, hippocampus, substantia nigra, Frontal Lobe • Loss of synapses (connections between neurons) • Mild degree of Alzheimer-type pathology

10. Causes of Memory Changes in Aging • Normal aging * • Neurodegenerative diseases / Alzheimer’s disease • Medications • Alcohol • Depression • Anxiety • Head trauma

11. Variability of Aging depends on: • Heredity: • Presence of longevity genes • Absence of disease genes • Lifestyle: • Diet • Body weight • Exercise • Luck: • Avoiding disease and trauma

12. Alzheimer’s disease Normal Aging Mild Cognitive Impairment No change over time Other dementias

13. Mild Cognitive Impairment • Variable defintion • Originally defined as a memory only syndrome • Defined loosely -include memory and cognitive problems, yet normal ability to do ADLs • Conversion to AD at a rate of about 10-15%/year • Normal elderly – 1-2% per year • The non- memory types are those at risk for other types of dementia

14. Why is identifying at MCI stage important? • Study the conversion of MCI to AD • Intervene with drugs • Predict who is at the greatest risk for developing the disease • It appears that intervention at the MCI stage may be more effective

15. What is Dementia? Loss of memory and other intellectual abilities serious enough to interfere with daily life Alzheimer’s is most common form of dementia

16. TYPES OF DEMENTIA • Degenerative • Non degenerative • Vascular Dementia • Bacterial/Viral infections • Syphilis, cryptococcus, Lyme Dz., Whipple’s Dz., HIV/AIDS, SSPE, PML, ect. • Prion disease (e.g., CJS) • Neoplasia (brain tumors, carcinomatos meningitis, paraneoplastic synd.) • Vitamin deficiency (e.g., Pellegra, B12 deficiency) • Endocrine deficiencies (e.g., Thyroid dz., Hashimoto’s encephalitis, Cushing’s) • Cerebral trauma (SDH, Concussions) • Toxins (Alcohol, drugs, heavy metals) • Others: NPH, Hydrocephalus, MS, Dialysis, Depression, TBI

17. Degenerative Diseases • Alzheimer’s disease (>60%) • Lewy Body Disease (20%) • FTLD (2-5%) • Parkinson’s disease and Dementia (PDD) • Huntington’s • PSP • Some others: CBGD, Kearns-Sayre, Hallervorden-Spatz, Wilson’s dz, etc.

18. What is AD? • AD Statistics…. • Most common cause of dementia among people age 65 and older. • 5.3 million people now have AD. • 1 out of 8 over 65; 1 out of 2 over 85 • For every 5-year age group beyond 65, the percentage of people with AD doubles. • By 2050, 13.2 million older Americans are expected to have AD if the current numbers hold and no preventive treatments become available.

19. Impact of AD Once considered a rare disorder, Alzheimer’s disease is now seen as a major public health problem that is seriously affecting millions of older Americans and their families.

20. AD and the Brain The Changing Brain in Alzheimer’s Disease No one knows what causes AD to begin, but we do know a lot about what happens in the brain once AD takes hold. Pet Scan of Normal Brain Pet Scan of Alzheimer’s Disease Brain

21. Medial Temporal Lobe

22. AD and the Brain Plaques and Tangles: The Hallmarks of AD The brains of people with AD have an abundance of two abnormal structures: • beta-amyloid plaques, which are dense deposits of protein and cellular material that accumulate outside and around nerve cells • neurofibrillary tangles, which are twisted fibers that build up inside the nerve cell An actual AD plaque An actual AD tangle

23. AD and the Brain Beta-amyloid Plaques Amyloid precursor protein (APP) is the precursor to amyloid plaque. 1.APP sticks through the neuron membrane. 2.Enzymes cut the APP into fragments of protein, including beta-amyloid. 3.Beta-amyloid fragments come together in clumps to form plaques. 1. 2. In AD, many of these clumps form, disrupting the work of neurons. This affects the hippocampus and other areas of the cerebral cortex. 3.

25. Ultimately the brain Shrinks

26. Risk factors for AD • ? Protective factors • NSAID use • Estrogen use • Statins • Anti-oxidants • Exercise • Diet • Mental activity • Psychosocial factors • Major Risks • Age • Family history • Genes (Apo E 4, others) • Minor Risks • Head trauma • Low education • Female sex

27. Genetics of AD • Genetic component (present in <10%) • ApoE4: stratifies risk of development, no guarantee • Presenilin 1 (most common) and 2 • Amyloid Precursor protein (chr.21) • Alpha 2 macroglobulin • all generally increase risk for early onset AD • More genes are being discovered

28. Warning Signs • Memory changes that disrupt daily life • Challenges in planning or solving problems • Difficult completing familiar tasks • Confusion with time or place • Trouble understanding visual images and spatial relationships

29. Warning Signs (cont.) • New problems with words • Misplacing things and losing ability to retrace steps • Decreased or poor judgement • Withdrawal from work or social activities • Changes in mood and personality

30. Evaluation • Informant history • MMSE (Folstein) & other Neuropsycholgical testing • Imaging • Activities of daily living (ADLs) • Medical history • Medication • Comorbidities

31. AD Research: Diagnosing AD Experienced physicians in specialized AD centers can now diagnose AD with > 90% accuracy. Early diagnosis has advantages: • Doctors can rule out other conditions that may cause dementia. • If it is AD, families have more time to plan for the future. • Treatments can start earlier, when they may be more effective. • It helps scientists learn more about the causes and development of AD.

32. Imaging • SPECT • Structural MRI / Volumetrics • Functional MRI • PET • PIB

33. Structural imaging MRI

34. Functional MRI

35. PET Scan

36. Positive PIB PET Negitive PIB PET MCI Non-progressor MCI

37. CSF and Peripheral Biomarkers • A Beta 42 (A beta Amyloid 1-42) • T-tau (total Tau) • P-Tau (phosphorylated tau) • Others to be validated

38. Treatments for Alzheimer’s Disease Cholesterase Inhibitors • Donepezil (Aricept) (5mg, 10mg, 23mg) • Rivastigmine (Exelon) (1.5mg x2, 3.0mg x2, 4.5mg x2, 6mg x2) • Rivastigmine Patch (Exelon patch) (4.6mg x2, 9.5mg x2) • Galantamine (Razadyne) (4mg x2, 8mg x2, 12mg x2) NMDA Receptor Antagonist • Mentantine (Namenda) (10mg x2)

39. Treatment Benefits • Individuals performed better on tests of memory and thinking • May delay or slow worsening of symptoms for about 6 – 12 months • People with moderate to severe AD may benefit slightly from taking memantine too

40. Issues in subjects with Dementia • Behavioral issues • Hallucinations • Sleep problems • Diminished appetite • Difficulty swallowing

41. Behavioral Problems • Very Common & Recurrent • Different manifestations • Active vs. Passive • Severity • Situational vs. Pervasive • Many sources and causes • Often related to Communication issues • Adverse consequences

42. Consequences of Untreated behavioral problems • Excess disability / disproportional presentation • Elevated caregiver depression & burder • Increased service utilization • Increased risk of institutionalization • Lower quality of life • Risk of harm to person or others

43. Underlying causes • Unmet needs, and frustrations (emotional & physical) • Environmental issues • cold/ warm • noise • Biological issues • other disease process • degenerative process

44. ABC model • Antecedents -Behaviors-Consequences • first describe the behavior well • Identify the antecedents and triggers • specify consequences / outcome responses • develop an action plan according to the person and environment

45. Treatment • What should not be done • Argue and or convince • Negative emotions from care giver • What is useful • Redirecting • Distracting • Drug Treatment

46. Primay Approach to Behavioral problesm • Proactive assessment (NPI) • Family psychoeducation • Caregiver support & referral (e.g. AA) • ABC approach • behavioral 1st then Pharmaceutical • Develop & document plan and goals • follow up and change plan regularly

47. AD Research: the Search for Causes Epidemiologic Studies Scientists examine characteristics, lifestyles, and disease rates of groups of people to gather clues about possible causes of AD. The NIA is currently funding epidemiologic studies in a variety of different groups. Two of the studies focus on religious communities. Researchers conduct yearly exams of physical and mental status, and studies of donated brains at autopsy. Some early results indicate: • Mentally stimulating activity protects the brain in some ways. • In early life, higher skills in grammar and density of ideas are associated with protection against AD in late life.

48. AD Research: Clinical Trials Clinical trials are the primary way that researchers find out if a promising treatment is safe and effective. • Trials examine approved drugs to see if they can be used for other purposes, or look at experimental drugs. • Participating in a trial means regular contact with the study team, who can provide state-of-the-art AD care.

49. AD Research: the Search for New Treatments Researchers also are looking at other treatments, including: • vaccine against AD. • cholesterol-lowering drugs called statins • anti-oxidants (vitamins) and folic acid • anti-inflammatory drugs • substances that prevent formation of beta-amyloid plaques • nerve growth factor to keep neurons healthy

50. Research at Loma Linda University • Looking at the influence of Diet and lifestyle on development of neurodegenerative diseases (Dementia, PD, etc), and Stroke • Community based approach to aging research and aging support • Novel Imaging approaches to early detection of Dementia • Clinical trials